Glycoprotein News and Research

RSS

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

People aren’t the only ones who should be social distancing — new research shows our cells need to as well. Researchers from Ohio State University in Columbus, Ohio, USA, used in-culture techniques to confirm SARS-CoV-2 transmission via cell-to-cell contact.

8 Jun 2021

What lessons have we learned over a year into the COVID-19 pandemic?

One of the pressing questions scientists are currently trying to answer is whether the current vaccines will remain effective against the emerging SARS-CoV-2 variants of concern. A new piece of research has been published in the journal Biomedicines, which discusses the knowledge we have gained thus far and the questions that researchers should address in future work.

8 Jun 2021

Distinct spike protein mutations in SARS-CoV-2 variant in Russia

Additionally, a novel variant has recently been characterized by researchers from Russia in the journal Viruses. The variant, first discovered in January 2021 in Northwest Russia, is characterized by distinct spike protein mutations.

7 Jun 2021

Natural products show promise against COVID-19 via iron chelation

Researchers at the University of Catania in Italy investigated whether natural compounds could prevent disease progression. Their study published in the Journal of Clinical Medicine found that iron chelators and protease inhibitors can counteract SARS-CoV-2 infection.

7 Jun 2021

Could COVID-19 vaccinations or prior infections protect against other coronaviruses?

A new study provides encouraging proof of the feasibility of this project, showing that both natural infection with and vaccination against SARS-CoV-2 are associated with an increase in cross-reactive antibodies against other CoVs.

7 Jun 2021

The great promise of antiviral peptides against SARS-CoV-2

A new study, recently published in the journal Viruses, describes the impressive evidence for the role of antimicrobial peptidse (AMPs) in the treatment of COVID-19.

7 Jun 2021

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

A new medRxiv* preprint reports the immunomodulatory effect of the E484K mutation newly acquired by the United Kingdom (U.K.) variant.

2 Jun 2021

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

A new bioRxiv* preprint reports on the successful use of a protocol to expand SARS-CoV-2-reactive T-cells a thousand-fold.

2 Jun 2021

Scientists test antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus

Army scientists working as part of an international consortium have developed and tested an antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus (CCHFV), which is carried by ticks and kills up to 60 percent of those infected.

2 Jun 2021

Researchers find natural metabolites help SARS-CoV-2 escape antibodies

An international team of scientists has identified a human molecule — biliverdin — as a potential severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) target. The binding of the heme metabolite to the N-terminal domain of SARS-CoV-2 is associated with the virus’s ability to dodge the immune system by suppressing antibody binding to the spike protein.

2 Jun 2021

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

New research from a team of scientists at the Centre for Research in Molecular Modeling, Department of Chemistry and Biochemistry, Concordia University in Canada, has aimed to determine the potential causes of anaphylaxis or allergic reactions reported in some individuals after receiving COVID-19 vaccines, including the mRNA vaccines by Pfizer-BioNTech and Moderna.

1 Jun 2021

SARS-CoV-2 variant B.1.617 may be more transmissible and pathogenic due to spike cleavage

In a new research paper currently available on the bioRxiv* preprint server, a research group from the United Kingdom (UK) provides experimental evidence that B.1.617 lineage of the severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2) – also known as the Indian variant of concern – shows enhanced cleavage of spike glycoprotein by furin, which can enhance its transmissibility and pathogenic traits.

31 May 2021

FDA approves targeted therapy for tumors with KRAS mutations

Today, the U.S. Food and Drug Administration approved Lumakras (sotorasib) as the first treatment for adult patients with non-small cell lung cancer whose tumors have a specific type of genetic mutation called KRAS G12C and who have received at least one prior systemic therapy.

29 May 2021

Researchers identify a novel SARS-CoV-2 variant (with the V1230L mutation) in West Bengal, India

Researchers analyzed 2,000 viral genomes of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the causative agent of coronavirus disease 2019 (COVID-19) – sequences obtained from India and found a new variant that could be more infectious and transmissible.

28 May 2021

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

A new study by researchers from Taiwan and the US suggests that the removal of unnecessary glycans from spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposes highly conserved sequences and opens the door for the development of broadly protective vaccines against the virus and its variants.

28 May 2021

Immunologists decode T cell responses that occur during COVID-19 infection

An international team of researchers from the Institute for Research in Biomedicine, affiliated to the Università della Svizzera italiana, has deciphered, at single cell resolution, the T cell responses occurring during COVID-19 infection.

26 May 2021

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Since COVID-19 was first detected in December 2019 in Wuhan, China, many different variants of its causative virus – SARS-CoV-2 – have emerged. Through increased viral fitness, some of these have risen to predominance over earlier variants in a remarkably short period of time. New research, by a team of scientists at major institutions in France, examines the reasons behind this phenomenon in one such variant of concern (VOC), the so-called UK variant.

25 May 2021

Little evidence for mRNA COVID-19 vaccine-associated thrombocytopenia, suggests new FDA study

Even as a host of vaccines have been rolled out to counter the coronavirus disease 2019 (COVID-19) pandemic, some serious adverse effects have been reported, in the form of thrombocytopenia. A new study in the journal Vaccine reports the results of an evaluation of reported cases of this condition, using data from the Vaccine Adverse Event Reporting System (VAERS).

24 May 2021

Genetically engineered intestinal organoids reveal potential treatment targets against SARS-CoV-2

Using CRISPR/Cas9 and human intestinal organoids to study genes implicated in the biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), researchers from the Netherlands identified a specific serine protease (TMPRSS2) as an attractive pan-coronavirus therapeutic target. Their exciting findings are available in a study currently available on the bioRxiv* preprint server.

24 May 2021

Research suggests Garcinia kola extract might suppress severe COVID-19 cytokine storms

Researchers in the UK and Nigeria have conducted a study showing that Garcinia kola seed extract and garcinoic acid may provide therapeutic benefits in the late stage of severe coronavirus disease 2019 (COVID-19) and other coronavirus infections.

24 May 2021

Glycoprotein News and Research

Cell-to-cell contact helps in spreading SARS-CoV-2, finds study

What lessons have we learned over a year into the COVID-19 pandemic?

Distinct spike protein mutations in SARS-CoV-2 variant in Russia

Natural products show promise against COVID-19 via iron chelation

Could COVID-19 vaccinations or prior infections protect against other coronaviruses?

The great promise of antiviral peptides against SARS-CoV-2

E484K mutation may confer immune evasion capability on UK variant of SARS-CoV-2

Large-scale expansion of spike-reactive T cells feasible after COVID-19 vaccination

Scientists test antibody-based therapy to treat Crimean-Congo hemorrhagic fever virus

Researchers find natural metabolites help SARS-CoV-2 escape antibodies

Scientists explain possible causes of anaphylaxis following mRNA COVID-19 vaccination

SARS-CoV-2 variant B.1.617 may be more transmissible and pathogenic due to spike cleavage

FDA approves targeted therapy for tumors with KRAS mutations

Researchers identify a novel SARS-CoV-2 variant (with the V1230L mutation) in West Bengal, India

Glycosylation a significant element in SARS-CoV-2 infection and vaccine design, says study

Immunologists decode T cell responses that occur during COVID-19 infection

SARS-CoV-2 UK variant may induce more inflammation, study suggests

Little evidence for mRNA COVID-19 vaccine-associated thrombocytopenia, suggests new FDA study

Genetically engineered intestinal organoids reveal potential treatment targets against SARS-CoV-2

Research suggests Garcinia kola extract might suppress severe COVID-19 cytokine storms

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News